Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future

Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in Pharmacology 2016-07, Vol.7 (197)
Hauptverfasser: de Bruijn, Winnie, Ibáñez, Cristina, Frisk, Pia, Bak Pedersen, Hanne, Alkan, Ali, Vella Bonanno, Patricia, Brkičić, Ljiljana S, Bucsics, Anna, Dedet, Guillaume, Eriksen, Jaran, Fadare, Joseph O, Fürst, Jurij, Gallego, Gisselle, Godói, Isabella P, Guerra Júnior, Augusto A, Gürsöz, Hakkı, Jones, Jan, Joppi, Roberta, Kerman, Saim, Laius, Ott, Madzikwa, Newman, Magnússon, Einar, Maticic, Mojca, Markovic-Pekovic, Vanda, Massele, Amos, Ogunleye, Olayinka, O'Leary, Aisling, Piessnegger, Jutta, Sermet, Catherine, Simoens, Steven, Tiroyakgosi, Celda, Truter, Ilse, Thyberg, Magnus, Tomekova, Kristina, Wladysiuk, Magdalena, Vandoros, Sotiris, Vural, Elif H, Zara, Corinne, Godman, Brian
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 2004 and 2011, enhanced by the launch of the protease inhibitors (PIs) boceprevir (BCV) and telaprevir (TVR) in addition to ribavirin and pegylated interferon (pegIFN). Costs will continue to rise with new treatments including sofosbuvir, which now include interferon free regimens.
ISSN:1663-9812
1663-9812